Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Olsalazine sodium is a small molecule anti-inflammatory drug in the aminosalicylate class, used primarily for the maintenance of remission in ulcerative colitis, especially in patients intolerant to sulfasalazine. It is a prodrug composed of two molecules of mesalamine (5-aminosalicylic acid) linked by an azo bond. After oral administration, colonic bacteria cleave this bond to release active mesalamine locally in the colon. Mesalamine exerts its effect by inhibiting cyclooxygenase (COX) and lipoxygenase pathways involved in arachidonic acid metabolism, thereby reducing prostaglandin and leukotriene production and attenuating inflammation at the epithelial level. Olsalazine also inhibits xanthine oxidase activity[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on olsalazine sodium.